Aventis Pharma S.a.

Rhone-Poulenc Sante

Rhone-Poulenc Rorer S.a.

Sanofi

Sanofi-Aventis

Novexel

Novexel Sa

Jean-Luc Malleron

Serge Mignani

Michel Tabart

Michel Evers

Fabrice Viviani

Youssef El-Ahmad

Jean-Francois Peyronel

Gerard Ponsinet

Arielle Genevois-Borella

Daniel Achard

Youssef El Ahmad

Marie-Therese Comte

Jean Bouquerel

Gerard Roussel

Augustin Hittinger

Claude Gueremy

Jean-Christophe Carry

Baptiste Ronan

Antony Bigot

Michel Barreau

Serge Grisoni

Alain Truchon

Guy Pantel

Daniel Farge

Hartmut Strobel

Kurt Ritter

Marc Capet

Eric Bacque

Herve Bouchard

Dominique Lesuisse

Sven Ruf

Marcel Patek

Michel Cheve

Gilles Doerflinger

Jacques Mauger

Conception Nemecek

Fahad A Al-Obeidi

Anil Nair

Mark Gabriel Palermo

Jean-Francois Sabuco

Andrees Bohme

Philippe Hubert

Thomas Faitg

Eric Bacqué

Andreas Karlsson

Gaetan Touyer

Daniel Bond

Didier Bénard

Christophe Daubi&eacute;

Corrine Terrier

Dominique Damour

Hervé Bouchard

Herv&eacute; Bouchard

Jean-Paul Martin

Philippe Girard

Sylvie Wentzler

Guy Picaut

Magali Mathieu

Didier Benard

St&eacute;phane Mutti

Greg Harlow

Serg Grisoni

Eric Bacqu&eacute;

Richard Labaudiniere

Jean-Francedillaois Peyronel

Jean-Marc Guillaume

Michel Kryvenko

Jean-Fran&ccedil;ois Desconclois

Marie-Iherese Comte

Veronique Fardin

Andre Crespo

Evelyne James-Surcouf

Bernard Baudoin

Anne Morgat

Jean-Francedillaois Sabuco

Eric Baque

Marc Pierre Lavergne

Fahad Al-Obeidi

Mark Palermo

The present invention relates to derivatives of 1-oxo-isoindoline-4-carboxamides and of 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamides, to the preparation thereof and to the therapeutic use thereof.

1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof

The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH, ORc, SRc, SORa, SORa, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSORa, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF, CHF, CHF, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them

The present invention relates to compounds of formula I, to the preparation thereof and to the therapeutic use thereof.

Derivatives of 1-OXO-1,2-dihydroisoquinoline-5-carboxamides and of 4-OXO-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics

The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to the novel derivatives of formula (I) in which  A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH, ORc, SRc, SORa, SORa, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSORa, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF, CHF, CHF, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The invention relates to 4-substituted quinoline compounds of general formula: which are active as antimicrobials, in which:

4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them

Quinolylpropylpiperidine derivatives of general formula (I) in which Ris hydrogen or fluorine, Ris carboxyl, carboxymethyl or hydroxymethyl, Ris alkyl substituted either with phenylthio optionally substituted with halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano or amino, or with cycloalkylthio (3 to 7 members) optionally substituted with halogen or trifluoromethyl, or with heteroarylthio (5 to 6 members and 1 to 4 heteroatoms chosen from N, O and S), optionally substituted with halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano or amino or Ris propargyl substituted by phenyl or heteroaryl as defined above and Ris alkyl, alkenyl-CH&#x2014; or alkynyl-CH&#x2014;, cycloalkyl or cycloalkylalkyl, in their various isomeric forms, separate or as mixtures, and also their salts, their preparation process and intermediates and the compositions containing them. These novel derivatives are potent antibacterial agents 

Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor

Heterocyclylalkylpiperidine derivatives of general formula (I)in their enantiomeric or diastereoisomeric forms or mixtures of these forms, and/or, where appropriate, in their syn or anti form or a mixture thereof, as well as any salt thereof.

Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them

Disclosed are azetidine derivatives of formula:their optical isomers, their salts, their preparation and medicaments containing them.

Acetindine derivatives, their preparation and medicaments containing them

Quinolylpropylpiperidine derivatives of general formula (I) in which Ris hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino and Ris hydrogen, or Rand Rform an oxo, Ris carboxyl, carboxymethyl or hydroxymethyl, Ris alkyl either substituted with phenylthio optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino, or with cycloalkylthio (3 to 7 members) optionally substituted with halogen or trifluoromethyl, or with heteroarylthio (5 to 6 members and 1 to 4 heteroatoms chosen from N, O and S), optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino or Ris propargyl substituted with phenyl or heteroaryl as defined above, Ris alkyl, alkenyl-CH&#x2014; or alkynyl-CH&#x2014;, cycloalkyl or cycloalkylalkyl, in their various isomeric forms, separate or as mixtures, and also their salts, their preparation process and intermediates and the compositions containing them. These novel derivatives are potent antibacterial agents.

Quinolylpropylpiperidine derivatives of general formula (I) are described, and are useful as antimicrobial agents. Their preparation is also described.

Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them

Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them

Growing community of inventors

Marcoussis, France

Jean-Luc Malleron